Orient Pharma Statistics

Total Valuation

Orient Pharma has a market cap or net worth of TWD 8.25 billion. The enterprise value is 8.73 billion.

Market Cap	8.25B
Enterprise Value	8.73B

Important Dates

The last earnings date was Thursday, November 28, 2024.

Earnings Date	Nov 28, 2024
Ex-Dividend Date	n/a

Share Statistics

Orient Pharma has 223.04 million shares outstanding. The number of shares has increased by 8.79% in one year.

Current Share Class	n/a
Shares Outstanding	223.04M
Shares Change (YoY)	+8.79%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	2.08%
Owned by Institutions (%)	n/a
Float	33.55M

Valuation Ratios

The trailing PE ratio is 69.29.

PE Ratio	69.29
Forward PE	n/a
PS Ratio	7.74
PB Ratio	4.66
P/TBV Ratio	6.50
P/FCF Ratio	56.87
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 31.24, with an EV/FCF ratio of 60.18.

EV / Earnings	73.33
EV / Sales	8.20
EV / EBITDA	31.24
EV / EBIT	60.64
EV / FCF	60.18

Financial Position

The company has a current ratio of 1.32, with a Debt / Equity ratio of 0.37.

Current Ratio	1.32
Quick Ratio	0.71
Debt / Equity	0.37
Debt / EBITDA	2.37
Debt / FCF	4.56
Interest Coverage	10.07

Financial Efficiency

Return on equity (ROE) is 6.97% and return on invested capital (ROIC) is 3.74%.

Return on Equity (ROE)	6.97%
Return on Assets (ROA)	3.48%
Return on Capital (ROIC)	3.74%
Revenue Per Employee	6.16M
Profits Per Employee	688,416
Employee Count	173
Asset Turnover	0.41
Inventory Turnover	2.03

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +82.31% in the last 52 weeks. The beta is 0.15, so Orient Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.15
52-Week Price Change	+82.31%
50-Day Moving Average	35.48
200-Day Moving Average	27.96
Relative Strength Index (RSI)	50.00
Average Volume (20 Days)	158,077

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Orient Pharma had revenue of TWD 1.07 billion and earned 119.10 million in profits. Earnings per share was 0.53.

Revenue	1.07B
Gross Profit	585.21M
Operating Income	144.02M
Pretax Income	151.31M
Net Income	119.10M
EBITDA	260.01M
EBIT	144.02M
Earnings Per Share (EPS)	0.53

Full Income Statement

Balance Sheet

The company has 180.54 million in cash and 661.70 million in debt, giving a net cash position of -481.16 million or -2.16 per share.

Cash & Cash Equivalents	180.54M
Total Debt	661.70M
Net Cash	-481.16M
Net Cash Per Share	-2.16
Equity (Book Value)	1.77B
Book Value Per Share	7.94
Working Capital	178.50M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 170.73 million and capital expenditures -25.61 million, giving a free cash flow of 145.12 million.

Operating Cash Flow	170.73M
Capital Expenditures	-25.61M
Free Cash Flow	145.12M
FCF Per Share	0.65

Full Cash Flow Statement

Margins

Gross margin is 54.92%, with operating and profit margins of 13.51% and 11.18%.

Gross Margin	54.92%
Operating Margin	13.51%
Pretax Margin	14.20%
Profit Margin	11.18%
EBITDA Margin	24.40%
EBIT Margin	13.51%
FCF Margin	13.62%

Dividends & Yields

Orient Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.79%
Shareholder Yield	-8.79%
Earnings Yield	1.44%
FCF Yield	1.76%

Stock Splits

The last stock split was on May 23, 2016. It was a reverse split with a ratio of 0.6500936135.

Last Split Date	May 23, 2016
Split Type	Reverse
Split Ratio	0.6500936135

Scores

Orient Pharma has an Altman Z-Score of 3.34.

Altman Z-Score	3.34
Piotroski F-Score	n/a